PremiumCompany AnnouncementsLabcorp Reports Q1 2025 Earnings and Strategic Growth Labcorp’s Earnings Call Highlights Growth and Innovation Morning Movers: Hims & Hers skyrockets following obesity pact with Novo Nordisk PremiumRatingsLabcorp Holdings: Buy Rating Maintained Amid Minimal Impact from FDA’s Animal Testing Phase-Out Labcorp price target lowered to $274 from $285 at Truist Labcorp Holdings Declares Cash Dividend for Shareholders PremiumCompany AnnouncementsLabcorp Holdings to Announce Q1 2025 Financial Results Labcorp to acquire certain assets of Opko Health’s BioReference Health Truist remains bullish on Labcorp after ‘another nice strategic acquisition’ 
